Since miR-29a is over-expressed in mesenchymal metastatic RasXT cells compared to epithelial EpRas cells, and also in breast cancer tissues 21, we questioned whether inhibition of miR29a could correct the TTP–HuR imbalance. The gene discussed is ELAVL1; the disease is breast carcinoma.